Travere Therapeutics (TVTX) Share-based Compensation (2016 - 2025)
Historic Share-based Compensation for Travere Therapeutics (TVTX) over the last 13 years, with Q3 2025 value amounting to $11.3 million.
- Travere Therapeutics' Share-based Compensation rose 4040.14% to $11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.6 million, marking a year-over-year increase of 1890.19%. This contributed to the annual value of $36.9 million for FY2024, which is 1657.32% down from last year.
- Travere Therapeutics' Share-based Compensation amounted to $11.3 million in Q3 2025, which was up 4040.14% from $10.6 million recorded in Q2 2025.
- In the past 5 years, Travere Therapeutics' Share-based Compensation ranged from a high of $13.5 million in Q1 2023 and a low of $7.0 million during Q3 2021
- In the last 5 years, Travere Therapeutics' Share-based Compensation had a median value of $9.3 million in 2022 and averaged $9.6 million.
- Per our database at Business Quant, Travere Therapeutics' Share-based Compensation soared by 7320.45% in 2022 and then plummeted by 2914.05% in 2024.
- Travere Therapeutics' Share-based Compensation (Quarter) stood at $7.4 million in 2021, then rose by 26.04% to $9.3 million in 2022, then decreased by 12.4% to $8.1 million in 2023, then grew by 13.14% to $9.2 million in 2024, then grew by 22.24% to $11.3 million in 2025.
- Its last three reported values are $11.3 million in Q3 2025, $10.6 million for Q2 2025, and $11.5 million during Q1 2025.